Hypothesis

The age-related somatopause is not merely a parallel decline to NAD+ loss; it actively orchestrates NAD+ depletion through a FOXO-dependent transcriptional program that raises CD38 and lowers NAMPT expression, thereby conserving resources by limiting NAD+-fueled processes such as PARP activation and pro‑inflammatory signaling.

Mechanistic Rationale

Reduced GH/IGF-1 signaling diminishes PI3K‑Akt activity, allowing increased nuclear translocation of FOXO transcription factors. FOXO proteins have been shown to bind promoters of CD38 and NAMPT in a context‑dependent manner: in aged tissues they upregulate CD38 (a NAD+ glycohydrolase) while repressing NAMPT (the rate‑limiting enzyme in the NAD+ salvage pathway) [4, 5]. This dual action creates a feed‑forward loop where NAD+ is both consumed faster and synthesized slower, reproducing the observed NAD+ decline without invoking random molecular damage.

From an evolutionary perspective, lowering NAD+ curtails PARP‑1 activity, which otherwise consumes large amounts of NAD+ during DNA repair, and reduces SIRT1‑driven deacetylation that can promote a senescent secretory phenotype. Thus, the cell deliberately scales back its "ambitions"—high‑energy repair and proliferative programs—to favor survival under deteriorating conditions, mirroring the lifespan‑extending effects of reduced IGF-1 signaling [1, 2].

Testable Predictions

1. Genetic – Liver‑specific IGF‑1R knockout in young mice will recapitulate the aged NAD+ phenotype (↑CD38, ↓NAMPT, ↓total NAD+) without altering GH levels.
2. Pharmacologic – Acute IGF‑1 administration to aged mice will decrease hepatic CD38 expression and increase NAMPT within 6 h, preceding any measurable rise in circulating IGF‑1.
3. Rescue – CD38 inhibition (e.g., with 78c) in IGF‑1R‑deficient mice will restore NAD+ to youthful levels but will not affect FOXO nuclear localization, confirming that NAD+ changes lie downstream of FOXO.
4. Functional – Mice with combined IGF‑1R loss and PARP‑1 haploinsufficiency will show no further NAD+ increase beyond PARP‑1 reduction alone, indicating that the NAD+ savings from somatopause are largely allocated to restraining PARP‑driven consumption.

Potential Experimental Approaches

• Perform ChIP‑seq for FOXO1/3 in livers of young vs. old mice to verify direct binding to the Cd38 and Nampt promoters.
• Use AAV‑shRNA to knock down NAMPT specifically in aged mice and assess whether exacerbating NAD+ loss worsens insulin resistance, testing whether the NAD+ drop is protective.
• Conduct longitudinal metabolomics in humans receiving low‑dose GH replacement, measuring CD38 activity (via circulating cADPR) and NAD+ metabolites to see if GH elevation reverses the predicted enzymatic shifts.

If these experiments fail to show that manipulating GH/IGF-1 signaling alters CD38/NAMPT expression and NAD+ levels in the predicted direction, the hypothesis would be falsified, supporting the view that NAD+ decline is an independent aging lesion rather than an adaptive downstream effect of somatopause.